Shares in biopharmaceutical company Viking Therapeutics (NASDAQ: VKTX) were up by 6.3% at 12:30 a.m. ET today. The move likely stems from the market digesting the previous day’s news that Viking had initiated a phase 3 trial of its most promising program in its pipeline, namely VK2375, a treatment for metabolic disorders, including obesity.
Why VK2375 is exciting investors
There are probably two key reasons why the market likes the initiation of a phase 3 trial:
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Learn More »
VK2375 is a dual GLP-1/GIP receptor agonist similar to Eli Lilly‘s blockbuster weight loss drug Zepbound.
Viking is developing VK2375 in both subcutaneous (under the skin) and oral formulations. The subcutaneous phase 3 trial is currently underway, while the phase 2 oral dosing trial results are expected to be released later this year.
For reference, Novo Nordisk also offers a highly successful weight loss drug, Wegovy, a GLP-1 receptor agonist.
What it means to investors
While Viking Therapeutics, with a $3.2 billion market capitalization, will face challenges in competing with Eli Lilly’s Zepbound unless it can demonstrate superior efficacy in the phase 3 trial, the real value in the business may lie in the oral formulation.
There are obvious convenience and accessibility advantages to an oral formulation over a subcutaneous one, and a successful phase 2 trial may encourage a much larger pharmaceutical company to consider acquiring the company to take it through phase 3.
Image source: Getty Images.
As such, look out for the phase 2 results later in the year. In addition, note that Novo Nordisk has submitted to the FDA for approval of an oral formulation of Wegovy , and Eli Lilly recently reported positive results in a phase 3 trial for an oral GLP-1 agonist, orforglipron.
All this means that the field is getting crowded.
Should you invest $1,000 in Viking Therapeutics right now?
Before you buy stock in Viking Therapeutics, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Viking Therapeutics wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004… if you invested $1,000 at the time of our recommendation, you’d have $687,731!* Or when Nvidia made this list on April 15, 2005… if you invested $1,000 at the time of our recommendation, you’d have $945,846!*
Now, it’s worth noting Stock Advisor’s total average return is 818% — a market-crushing outperformance compared to 175% for the S&P 500. Don’t miss out on the latest top 10 list, available when you join Stock Advisor.
See the 10 stocks »
*Stock Advisor returns as of June 23, 2025
Lee Samaha has no position in any of the stocks mentioned. The Motley Fool recommends Novo Nordisk and Viking Therapeutics. The Motley Fool has a disclosure policy.
